Polymyalgia rheumatica and polymyalgia-like syndromes as adverse events following COVID-19 vaccines: Working notes from a narrative review of published literature

9Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

Abstract

Since the 1990s, polymyalgia rheumatica (PMR) has been reported as a possible adverse event following immunization (AEFI). The aim of this narrative review is to provide an overview of PMR (and PMR-like syndromes) following the most common types of COVID-19 vaccines, namely mRNA (tozinameran and mRNA-1273) and adenovirus-vectored (ChAdOx1-S) vaccines. To date, published literature reports few cases of PMR as vaccine-linked AEFI. Yet Vigibase, the WHO pharmacovigilance database, reports a few hundred cases. Based on these data, we address the question whether PMR/PMR-like syndromes following COVID-19 vaccines can be a true adverse or a coincidental event, and discuss its possible pathogenetic mechanisms.

Cite

CITATION STYLE

APA

Manzo, C., Castagna, A., & Isetta, M. (2022). Polymyalgia rheumatica and polymyalgia-like syndromes as adverse events following COVID-19 vaccines: Working notes from a narrative review of published literature. Reumatologia. Termedia Publishing House Ltd. https://doi.org/10.5114/reum.2022.115665

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free